Stock ACST ACASTI PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Acasti Pharma Inc.

Equities

ACST

CA00430K8656

Market Closed - Nasdaq
Other stock markets
 21:30:00 16/05/2024 BST 		5-day change 1st Jan Change
2.76 USD +2.22% Intraday chart for Acasti Pharma Inc. -4.50% -4.50%
02-12 Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
02-07 Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
AQ
Acasti: Fiscal Q3 Earnings Snapshot
AQ
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target
MT
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
AQ
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial
CI
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer
CI
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
AQ
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Acasti: Fiscal Q2 Earnings Snapshot
AQ
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
AQ
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal
MT
Aker BioMarine acquires patents, equipment, and scientific data from Acasti Pharma Inc
AQ
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
AQ
Acasti Pharma Inc. Announces Board Changes
CI
Transcript : Acasti Pharma Inc. - Special Call
Transcript : Acasti Pharma Inc. - Shareholder/Analyst Call
Acasti Pharma to Host KOL Event on GTX-104, A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage
AQ
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACST Stock
  4. News Acasti Pharma Inc.